Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Down 58.7% in August

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a large drop in short interest in August. As of August 14th, there was short interest totaling 108,801 shares, a drop of 58.7% from the July 30th total of 263,441 shares. Currently, 11.9% of the company’s stock are short sold. Based on an average trading volume of 13,826,443 shares, the days-to-cover ratio is presently 0.0 days.

Analysts Set New Price Targets

Several research firms have recently weighed in on AMIX. Wall Street Zen cut shares of Autonomix Medical to a “strong sell” rating in a report on Saturday. Zacks Research upgraded shares of Autonomix Medical to a “hold” rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $42.00.

Autonomix Medical Stock Down 5.5%

AMIX traded down $0.31 during midday trading on Friday, reaching $5.32. The company had a trading volume of 311,995 shares, compared to its average volume of 9,370,103. The business has a 50-day moving average of $6.34 and a two-hundred day moving average of $7.56. Autonomix Medical has a 1 year low of $2.44 and a 1 year high of $32.55. The company has a market cap of $5.16 million, a P/E ratio of -0.13 and a beta of -1.17.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.38. On average, equities research analysts predict that Autonomix Medical will post -20.17 EPS for the current year.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.